ES2138661T3 - Formulaciones de dosis elevadas. - Google Patents

Formulaciones de dosis elevadas.

Info

Publication number
ES2138661T3
ES2138661T3 ES94916722T ES94916722T ES2138661T3 ES 2138661 T3 ES2138661 T3 ES 2138661T3 ES 94916722 T ES94916722 T ES 94916722T ES 94916722 T ES94916722 T ES 94916722T ES 2138661 T3 ES2138661 T3 ES 2138661T3
Authority
ES
Spain
Prior art keywords
high dose
dose formulations
mycophenolic acid
mycophenolate mofetil
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916722T
Other languages
English (en)
Inventor
Glenn Jay Samuels
Jung-Chung Lee
Charles Lee
Stephen Berry
Paul Joseph Jarosz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Application granted granted Critical
Publication of ES2138661T3 publication Critical patent/ES2138661T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EL MICOFENOLATO MOFETIL, EL ACIDO MICOFENOLICO, Y LA RANOLAZINA PUEDEN DAR LUGAR MEDIANTE EL PROCESO DE ELABORACION ADECUADO A FORMULACIONES ORALES DE ALTA DOSIS MEDIANTE EL RELLENO CON UN PRODUCTO DE FUSION CALIENTE DE MOFETIL MICOFENOLATO SOBREENFRIADO, ACIDO MICOFENOLICO, LIQUIDO DE RANOLAZINA DANDO LUGAR A UN FORMATO DE DOSIS FARMACEUTICA. DE ESTE MODO SE DESCUBREN FORMULACIONES FARMACEUTICAS DE ALTAS DOSIS, Y METODOS DE FABRICACION DE LAS MISMAS.
ES94916722T 1993-05-13 1994-05-10 Formulaciones de dosis elevadas. Expired - Lifetime ES2138661T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/061,656 US5455045A (en) 1993-05-13 1993-05-13 High dose formulations

Publications (1)

Publication Number Publication Date
ES2138661T3 true ES2138661T3 (es) 2000-01-16

Family

ID=22037233

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916722T Expired - Lifetime ES2138661T3 (es) 1993-05-13 1994-05-10 Formulaciones de dosis elevadas.

Country Status (23)

Country Link
US (3) US5455045A (es)
EP (1) EP0697866B1 (es)
JP (1) JP3584037B2 (es)
KR (1) KR100296214B1 (es)
CN (1) CN1045884C (es)
AT (1) ATE187067T1 (es)
AU (1) AU674960B2 (es)
BR (2) BR9406604A (es)
CZ (1) CZ285297B6 (es)
DE (1) DE69421918T2 (es)
DK (1) DK0697866T3 (es)
ES (1) ES2138661T3 (es)
FI (1) FI114286B (es)
GR (1) GR3032021T3 (es)
HU (2) HU226470B1 (es)
IL (1) IL109639A (es)
NO (1) NO308828B1 (es)
NZ (1) NZ266683A (es)
PL (1) PL175583B1 (es)
PT (1) PT697866E (es)
RU (1) RU2135182C1 (es)
TW (1) TW434010B (es)
WO (1) WO1994026266A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0487575T3 (da) * 1989-08-17 1994-11-28 Cortecs Ltd Farmaceutiske formuleringer
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
WO1996031197A1 (en) * 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
JP2004505886A (ja) 2000-02-18 2004-02-26 スィーヴィー　セラピューティクス　インコーポレイテッド 鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6638970B2 (en) 2000-02-22 2003-10-28 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
US6677343B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
EP2332540A1 (en) * 2002-05-21 2011-06-15 Cv Therapeutics, Inc. Administration of ranolazine for the treatment of diabetes
DE60314662T2 (de) * 2002-12-05 2008-03-13 CV Therapeutics, Inc., Palo Alto Substituierte piperazinverbindungen und deren verwendung als fettsäureoxidationsinhibitoren
US7205303B2 (en) * 2003-01-03 2007-04-17 Cv Therapeutics, Inc. Substituted heterocyclic compounds
CA2513529A1 (en) * 2003-01-17 2004-08-19 Cv Therapeutics Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
AU2004252102A1 (en) * 2003-06-23 2005-01-06 Gilead Palo Alto, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
JP2007514769A (ja) 2003-12-18 2007-06-07 シーブイ・セラピューティクス・インコーポレイテッド １−アルカン−２−オール置換ピペラジンおよびピペリジン化合物
WO2005105768A2 (en) * 2004-04-26 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolic acid and ester derivatives thereof
WO2005105769A2 (en) * 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg - Mycophenolate mofetil impurity
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
CA2573781A1 (en) * 2004-07-20 2006-02-02 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Processes for preparation of crystalline mycophenolate sodium
AU2005282492A1 (en) * 2004-09-08 2006-03-16 Gilead Palo Alto, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
CN101098682A (zh) * 2005-01-06 2008-01-02 Cv医药有限公司 包括雷诺嗪的缓释药物制剂
CN100393312C (zh) * 2005-04-18 2008-06-11 吴建梅 霉酚酸或其类似物的软胶囊及其制备方法
US20080280977A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
JP2009542605A (ja) * 2006-07-06 2009-12-03 アレス トレーディング ソシエテ アノニム アニリノ−ピリミジンの経口医薬組成物、その製法、及びその使用
WO2008022284A2 (en) * 2006-08-16 2008-02-21 Aspreva Pharmaceuticals Ltd. Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080214555A1 (en) * 2007-02-13 2008-09-04 Markus Jerling Use of ranolazine for the treatment of cardiovascular diseases
WO2008101008A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20090076000A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched mycophenolate mofetil
AR068745A1 (es) * 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
US20100010082A1 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
US9012192B2 (en) * 2008-08-26 2015-04-21 Intelligentnano Inc. Ultrasound enhanced growth of microorganisms
US8962290B2 (en) 2008-08-26 2015-02-24 Intelligentnano Inc. Enhanced animal cell growth using ultrasound
CA2735412A1 (en) * 2008-08-26 2010-03-04 Intelligentnano Inc. Enhanced animal cell growth using ultrasound
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン
MX2011008554A (es) * 2009-05-19 2011-10-06 Celgene Corp Formulaciones de 4-amino-2-(2,6-dioxopiperidin-3-il) isoindolin-1,3-diona.
WO2010137040A2 (en) 2009-05-28 2010-12-02 Lupin Limited Novel pharmaceutical compositions of ranolazine
EP2480234B1 (en) 2009-09-25 2020-02-26 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
JP2023542418A (ja) 2020-09-27 2023-10-06 中国石油化工股▲ふん▼有限公司 不均化およびトランスアルキル化触媒、ならびに調製、ならびにそれらの利用
CN114456835B (zh) 2020-10-22 2023-06-06 中国石油化工股份有限公司 一种汽油组分的处理系统和处理方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
JPS5542995B2 (es) * 1972-02-24 1980-11-04
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
US4002718A (en) * 1974-10-16 1977-01-11 Arnar-Stone Laboratories, Inc. Gelatin-encapsulated digoxin solutions and method of preparing the same
US4145918A (en) * 1976-09-07 1979-03-27 Akzona Incorporated Freeze-thaw indicator
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
CA1125698A (en) * 1978-03-09 1982-06-15 Masaru Yoshida Process for preparing a polymer composition
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
DK164642C (da) * 1984-08-30 1992-12-14 Merrell Dow Pharma Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
DE3613799C1 (de) * 1986-04-24 1987-09-03 Nattermann A & Cie Verwendung von Glycofurol zum Verfluessigen von Arzneimittelzubereitungen fuer das Abfuellen in Weichgelatinekapseln
US4727069A (en) * 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US5175000A (en) * 1987-06-30 1992-12-29 Vipont Pharmaceutical, Inc. Free amine benzophenanthridine alkaloid compositions
US4936074A (en) * 1988-11-17 1990-06-26 D. M. Graham Laboratories, Inc. Process for preparing solid encapsulated medicament
US5053419A (en) * 1989-03-31 1991-10-01 The Children's Medical Center Corporation Treatment of AIDS dementia, myelopathy and blindness
EP0497977B1 (en) * 1989-10-26 1995-03-15 Nippon Shinyaku Company, Limited Gastric preparation
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
DK0542860T3 (da) * 1990-08-10 1999-02-15 Anormed Inc Immunosuppressive sammensætninger
US5247083A (en) * 1992-07-10 1993-09-21 Syntex (U.S.A.) Inc. Direct esterification of mycophenolic acid
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5467037A (en) * 1994-11-21 1995-11-14 International Business Machines Corporation Reset generation circuit to reset self resetting CMOS circuits

Also Published As

Publication number Publication date
CZ285297B6 (cs) 1999-06-16
KR960702304A (ko) 1996-04-27
IL109639A0 (en) 1994-08-26
NO954546L (no) 1995-11-10
NZ266683A (en) 1996-08-27
GR3032021T3 (en) 2000-03-31
KR100296214B1 (ko) 2001-10-24
RU2135182C1 (ru) 1999-08-27
CN1122571A (zh) 1996-05-15
JP3584037B2 (ja) 2004-11-04
CZ295495A3 (en) 1996-02-14
HU226470B1 (en) 2008-12-29
FI955439A0 (fi) 1995-11-10
HUT72978A (en) 1996-06-28
AU6830194A (en) 1994-12-12
US5554384A (en) 1996-09-10
FI114286B (fi) 2004-09-30
JPH08510254A (ja) 1996-10-29
DK0697866T3 (da) 2000-04-17
ATE187067T1 (de) 1999-12-15
FI955439A (fi) 1995-11-10
EP0697866B1 (en) 1999-12-01
IL109639A (en) 1998-02-08
TW434010B (en) 2001-05-16
BR1100723A (pt) 2000-04-18
EP0697866A1 (en) 1996-02-28
PL175583B1 (pl) 1999-01-29
AU674960B2 (en) 1997-01-16
DE69421918D1 (de) 2000-01-05
NO954546D0 (no) 1995-11-10
PT697866E (pt) 2000-04-28
BR9406604A (pt) 1996-01-02
US5455045A (en) 1995-10-03
HU211270A9 (en) 1995-11-28
US5472707A (en) 1995-12-05
NO308828B1 (no) 2000-11-06
HU9503224D0 (en) 1996-01-29
PL311654A1 (en) 1996-03-04
CN1045884C (zh) 1999-10-27
WO1994026266A1 (en) 1994-11-24
DE69421918T2 (de) 2000-03-30

Similar Documents

Publication Publication Date Title
ES2138661T3 (es) Formulaciones de dosis elevadas.
NO177177C (no) Fremgangsmåte for fremstilling av en flytende doseringsform for oral administrasjon av en farmasöytisk substans
DE3484779D1 (de) Pharmazeutische mittel.
IT8921132A0 (it) Inalatore per medicamenti in capsule.
ATE2667T1 (de) Antidepressiv wirkende derivate des trans-4phenyl-1,2,3,4-tetrahydro-1-naphthalin-amins und pharmazeutische zusammensetzungen daraus.
IT1212778B (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
DE3682083D1 (de) Pharmazeutische zusammensetzungen.
DE3583765D1 (de) Hydantoinderivate und diese enthaltende pharmazeutische zusammensetzungen.
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
CA2162670A1 (en) High dose formulations of mycophenolate mofetil, mycophenolic acid and ranolazine
IT8722647A0 (it) Composizione farmaceutica per somministrazione nasale.
LV10917A (lv) Bambuterina pielietojums lipidu saturu pazeminosu farmaceitisku kompoziciju pagatavosanai
IT8026232A0 (it) Composizioni farmaceutiche. derivato dell'alfa-mercapto propionilglicina ad attivita'terapeutica, procedimento per lasua preparazione e relative
DE3670083D1 (de) Pharmazeutische pyrrolizidinverbindungen und -zusammensetzungen und ihre herstellung.
IT8719352A0 (it) Nuovi composti ad attivita'colinergica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
IT8520150A0 (it) Nuovi derivati ad attivita'terapeutica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
IT8619383A0 (it) Nuovi composti ad attivita'colinergica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
IT8819541A0 (it) Composizione farmaceutica per somministrazione nasale.
IT8421319V0 (it) Capsula perfezionata per chiusure di sicurezza di flaconi ad uso medicinale.
ATE47399T1 (de) Carboxyalkyldipeptide, deren herstellung und deren pharmazeutische zusammensetzungen.
DE3581183D1 (de) Pulverige pharmazeutische zusammensetzung zur anwendung auf die schleimhaut der mund- oder nasenhoehle.
IT8125931A0 (it) Piperazine asimmetriche adattivita' farmacologica, procedimento per la loro preparazione e composizioni farmaceutiche relative.
ATE66213T1 (de) Hydantoinderivate und diese enthaltende pharmazeutische zusammensetzungen.
IT1166217B (it) Composizione farmaceutica per la terapia delle sterilita' maschile
ES262105Y (es) "dispositivo aplicable al llenado de capsulas medicamentosas".

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 697866

Country of ref document: ES